Use of Retained Earnings for Research and Development, Product Development and Capital Investment
First written in FY2016. 19 of 26 entries say "Advanced", first in FY2019. Latest entry: FY2026.
21 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「As a result, R&D expenses for the fiscal year were ¥696 million.」
R&D expenses were ¥696 million, up from ¥644 million in the previous year. The company also continues to use internal funds for product development and capital investment. - FY2025AdvancedAnnual report
「As a result, R&D expenses for the fiscal year were ¥644 million.」
The company recorded R&D expenses of ¥644 million for the year and continues to use internal funds for R&D. - FY2025-H1RestatedAnnual report
「Total R&D expenses for the six-month interim period were ¥306 million. There were no material changes in the status of the Group's R&D activities during the six-month interim period.」
The company recorded R&D expenses of ¥306 million and stated that there were no material changes in the status of its R&D activities. - FY2024-Q3AdvancedAnnual report
「Total R&D expenses for the nine-month period ended Q3 were ¥495 million.」
The company disclosed R&D expenses of ¥495 million for the nine-month period ended Q3 and continues to allocate funds to R&D. - FY2024-Q2AdvancedAnnual report
「Total R&D expenses for the six-month period ended Q2 were ¥316 million. This reflected an increase in funds of ¥300 million, mainly from proceeds from the sale and redemption of marketable securities, offset by a decrease in funds resulting from ¥1,085 million in expenditures for the acquisition of tangible and intangible fixed assets and a net outflow of ¥276 million from the acquisition, sale and redemption of investment securities.」
The company recorded R&D expenses of ¥316 million for the six-month period ended Q2 and spent ¥1,085 million on the acquisition of tangible and intangible fixed assets. - FY2024-Q1RestatedAnnual report
「Total R&D expenses for the three-month period ended Q1 were ¥155 million. There were no material changes in the status of the Group's R&D activities during the three-month period ended Q1.」
The company disclosed R&D expenses of ¥155 million for the three-month period ended Q1 and stated that there were no material changes in its R&D activities. - FY2023AdvancedAnnual report
「As a result, R&D expenses for the fiscal year were ¥653 million.」
R&D expenses for the year were ¥653 million, up from ¥632 million in the previous year. - FY2023-Q3AdvancedAnnual report
「Total research and development expenses for the nine-month period ended [current third quarter] amounted to ¥480 million.」
The company disclosed R&D expenses of ¥480 million for the nine-month period ended Q3 and continues to allocate funds to R&D. - FY2023-Q2AdvancedAnnual report
「Total research and development expenses for the six-month period ended [current second quarter] amounted to ¥310 million.」
The company recorded ¥310 million in research and development expenses for the six-month period ended [current second quarter], continuing to use funds for research and development. - FY2023-Q1AdvancedAnnual report
「Total research and development expenses for the three-month period ended [current first quarter] amounted to ¥157 million.」
The company recorded ¥157 million in research and development expenses for the three-month period ended [current first quarter], specifically disclosing the use of funds for research and development. - FY2022AdvancedAnnual report
「As a result, research and development expenses for the consolidated fiscal year amounted to ¥632 million.」
The company recorded ¥632 million in research and development expenses and ¥1,216 million in capital investment and other investments for the year, continuing to use funds for research and development, product development, and capital investment. - FY2022-Q3AdvancedAnnual report
「Total research and development expenses for the nine-month period ended [current third quarter] amounted to ¥465 million.」
The company recorded ¥465 million in research and development expenses for the nine-month period ended [current third quarter], specifically disclosing the use of funds for research and development. - FY2022-Q2AdvancedAnnual report
「Total research and development expenses for the six-month period ended [current second quarter] amounted to ¥313 million.」
The company recorded ¥313 million in research and development expenses for the six-month period ended [current second quarter], continuing to use funds for research and development. - FY2022-Q1AdvancedAnnual report
「The total R&D expenses for the three-month cumulative consolidated period were ¥155 million.」
The company recorded ¥155 million in research and development expenses for the three-month period ended [current first quarter], specifically disclosing the use of funds for research and development. - FY2021AdvancedAnnual report
「As a result, research and development expenses for the consolidated fiscal year amounted to ¥640 million.」
The company recorded ¥640 million in research and development expenses and made total capital investment and other investments of ¥1,612 million. - FY2021-Q3AdvancedAnnual report
「Total research and development expenses for the cumulative third quarter of the current fiscal year were ¥484 million.」
The company disclosed research and development expenses of ¥484 million for the nine-month period ended [current third quarter], continuing to use funds for research and development. - FY2021-Q2AdvancedAnnual report
「Total research and development expenses for the six-month period ended [current second quarter] amounted to ¥322 million.」
The company recorded ¥322 million in research and development expenses for the six-month period ended [current second quarter], specifically disclosing the use of funds for research and development. - FY2021-Q1AdvancedAnnual report
「Total research and development expenses for the three-month period ended [current first quarter] amounted to ¥156 million.」
The company recorded ¥156 million in research and development expenses for the three-month period ended [current first quarter], specifically disclosing the use of funds for research and development. - FY2020-Q3AdvancedAnnual report
「Total research and development expenses for the nine-month period ended [current third quarter] amounted to ¥529 million.」
The company disclosed research and development expenses of ¥529 million for the nine-month period ended [current third quarter], specifically demonstrating the use of funds for research and development. - FY2020-Q2AdvancedAnnual report
「Total research and development expenses for the six-month period ended [current second quarter] amounted to ¥349 million.」
The company recorded ¥349 million in research and development expenses for the six-month period ended [current second quarter], specifically disclosing the use of internal funds for research and development. - FY2019AdvancedAnnual report
「As a result, research and development expenses for the consolidated fiscal year amounted to ¥706 million.」
The company recorded ¥706 million in research and development expenses and ¥2,135 million in capital investment, using retained earnings for product development, capital investment, and other purposes. - FY2018RestatedAnnual report
「The company will use retained earnings for research and development, product development, and capital investment to sustain business growth over the long term, seek to improve return on equity through increased sales and improved profitability, and secure shareholder returns from a long-term, comprehensive perspective.」
The company reconfirmed its policy of using retained earnings for research and development, product development, and capital investment to improve sales, profitability, and return on equity. - FY2017RestatedAnnual report
「The company will use retained earnings for research and development, product development, and capital investment to sustain business growth over the long term, and seek to improve return on equity through increased sales and improved profitability」
The company reconfirmed its policy of directing retained earnings to research and development, product development, and capital investment to improve sales, profitability, and return on equity. - FY2016First statedAnnual report
「The company will use retained earnings for research and development, product development, and capital investment to sustain business growth over the long term, seek to improve return on equity through increased sales and improved profitability, and secure shareholder returns from a long-term, comprehensive perspective.」
The company plans to direct retained earnings to growth investment, leading to higher sales, improved profitability, and increased return on equity.